Author： Bannwarth Bernard Kostine Marie Poursac Nicolas
Publisher： Informa Healthcare
ISSN： 1742-5255
Source： Expert Opinion on Drug Metabolism and Toxicology, Vol.9, Iss.6, 2013-06, pp. : 753-761
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Benefit-Risk Assessment of Infliximab in the Treatment of Rheumatoid Arthritis
By Mikuls T.R.
Drug Safety, Vol. 26, Iss. 1, 2003-01 ,pp. :
Access to resources
Recommend
